The MCS-CANMOVE project aims to develop two new therapeutic agents: bivalent ligands for the treatment of movement disorders, such as levodopa-induced dyskinesia (LID) and restless legs syndrome (RLS), and drug delivery systems for the treatment of cancers, such as metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC). In both cases, a controlled multivalent strategy will be employed to improve selectivity and efficacy. LID and RLS are clinically challenging to treat, and current therapeutic solutions present undesirable side effects. Bivalent ligands will selectively and simultaneously modulate receptor dimers involved in the development of these diseases, thereby minimizing side effects. TNBC and mCRC share characteristics such as poor prognosis, metastasis, and chemoresistance. The proposed drug delivery systems are designed to selectively eradicate tumors and cancer stem cells, creating more effective therapies with fewer side effects.